Researchers have identified a “megacluster” of genes in Streptomyces soil bacteria that produces a coordinated suite of four antibiotics and one protein, all targeting the production of vitamin B7. Published in Nature, the study suggests this evolutionary mechanism could provide a new template for creating antibiotics that are significantly harder for multidrug-resistant pathogens to bypass.
How does targeting vitamin B7 stop bacteria?
The gene cluster functions by attacking multiple stages of biotin (vitamin B7) synthesis, an essential metabolic process for bacterial cell growth. According to Brendan Wren, a microbiologist at the London School of Hygiene & Tropical Medicine, it is difficult for bacteria to evolve resistance when an antibiotic simultaneously strikes several parts of a vital pathway.
The cluster produces four distinct antibiotic families—acidomycin, α-Me-KAPA, dapamycins, and the known class stravidins—alongside the protein streptavidin. By hitting these targets at once, the bacteria face a biological “pincer movement” that makes survival unlikely for the pathogen.
Streptomyces bacteria were also the source of streptomycin, which became the first effective medical treatment for tuberculosis in the 1940s.
Why is this discovery considered “hidden in plain sight”?
Streptomyces is one of the most thoroughly researched bacterial genera in history, yet this specific gene grouping went unnoticed for decades. Mark Blaskovich, an antibiotic researcher at the University of Queensland, notes that the system was effectively hiding in plain sight despite the extensive study of the genus.
Eric Brown, a biochemist at McMaster University and co-author of the study, spent decades investigating biotin metabolism. His team ultimately identified the megacluster while analyzing stravidins. They confirmed the cluster’s function by cloning a 65,808-base-pair segment of DNA and inserting it into a laboratory strain of Streptomyces, proving the genes were responsible for the multi-antibiotic output.
What are the future implications for antibiotic development?
The discovery offers a roadmap for “combination therapy” designed by nature itself. Evolution has already optimized these compounds to work in tandem, which may allow scientists to develop novel drug combinations that mirror these natural defenses, according to Blaskovich.
The researchers found similar gene clusters across multiple Streptomyces species, indicating that this defensive mechanism has been conserved through evolution. This suggests that other metabolic processes could potentially be targeted by similar undiscovered gene clusters, providing a new pipeline for future antimicrobial drugs.
When tracking antibiotic research, look for studies that focus on “metabolic pathways” rather than single-target inhibitors. Multi-target approaches are currently the primary focus for overcoming the rising threat of multidrug-resistant infections.
Frequently Asked Questions
- Why is it hard for bacteria to develop resistance to this cluster?
Because the cluster attacks multiple stages of the same metabolic pathway simultaneously, a single mutation is rarely enough for the bacteria to survive, according to Brendan Wren. - What is the significance of the 65,808 base pair DNA segment?
This segment contained the entire “megacluster.” Cloning it allowed researchers to prove that the specific grouping of genes was responsible for creating the four antibiotics and the protein. - Are these antibiotics ready for human use?
Not yet. The study identifies the potential of these compounds, but further clinical research is required to determine safety and efficacy in human patients.
Have questions about the future of antibiotic research? Join the conversation in the comments below or subscribe to our newsletter for the latest updates on medical breakthroughs.
